Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088972 · ClinicalTrials.gov registry record · Phase 2
S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00088972 is a Phase 2 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 8 participants.
The verdict
NCT00088972, a Phase 2 study, was terminated before completion, sponsored by SWOG Cancer Research Network.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be effective in preventing breast cancer. PURPOSE: This randomized phase II trial is studying how well celecoxib works in preventing breast cancer in premenopausal women who are at risk for developing the disease.
Interventions
- OTHER placebo
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2004-11 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088972
The ClinicalTrials.gov registry entry for NCT00088972 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00088972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088972 about?
NCT00088972 is a clinical study titled "S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be effective in preventing breast cancer. PURPOSE: This randomized phase II trial is studying how well celecoxib works in preventing breast cancer in pr...
What is the current status of trial NCT00088972?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2004-11. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00088972?
The interventions under investigation include: placebo (OTHER), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00088972?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.